These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Meta-Analysis Comparing P2Y Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225 [TBL] [Abstract][Full Text] [Related]
8. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH; Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257 [TBL] [Abstract][Full Text] [Related]
10. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Westman PC; Lipinski MJ; Torguson R; Waksman R Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137 [TBL] [Abstract][Full Text] [Related]
11. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative. Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164 [TBL] [Abstract][Full Text] [Related]
12. Ticagrelor as Compared to Clopidogrel Following Percutaneous Coronary Intervention for Acute Coronary Syndrome. Wiens EJ; Leon SJ; Whitlock R; Tangri N; Shah AH Am J Cardiol; 2023 Jul; 198():26-32. PubMed ID: 37196530 [TBL] [Abstract][Full Text] [Related]
13. The role of prasugrel in the management of acute coronary syndromes: a systematic review. Spartalis M; Tzatzaki E; Spartalis E; Damaskos C; Athanasiou A; Moris D; Politou M Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4733-4743. PubMed ID: 29131238 [TBL] [Abstract][Full Text] [Related]
15. Risk of major adverse cardiovascular events of Biswas M; Kali MSK; Biswas TK; Ibrahim B Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772 [TBL] [Abstract][Full Text] [Related]
16. Frequency and Reasons of Dual Antiplatelet Therapy Discontinuation and Switching of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome Treated with Stent Implantation. Fuertes Ferre G; Caballero Jambrina I; Ruiz Aranjuelo A; Jimeno Sánchez J; Galache Osuna JG; Andrés Esteban EM; Casasnovas Lenguas JA; Diarte de Miguel JA Cardiology; 2019; 142(4):203-207. PubMed ID: 31266007 [TBL] [Abstract][Full Text] [Related]
17. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Malik AH; Gupta R; Chakraborty S; Mahajan P; Bandyopadhyay D; Yandrapalli S; Zaid S; Sreenivasan J; Chaturvedi A; Mehta SS; Vyas AV; Patel NC; Combs WG; Ahmad H Cardiovasc Revasc Med; 2022 Aug; 41():115-121. PubMed ID: 35033458 [TBL] [Abstract][Full Text] [Related]
18. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis. Wang Z; Zhou DY; Su Y; Si LY; Xu Q BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560 [TBL] [Abstract][Full Text] [Related]
19. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191 [TBL] [Abstract][Full Text] [Related]